Dock and Lock Bispecific Antibody (DNL BsAb)

As a world leading biotech company, Creative Biolabs has established dock and lock technology platform for the generation of dock and lock bispecific antibody (DNL BsAb) products. Our experienced scientists in bispecific antibody development field can provide first class services tailored according to your needs.

Our DNL bispecific antibody is designed by utilizing the specific interaction between the regulatory (R) subunits of cAMP-dependent protein kinase (PKA) and the anchoring domains of A kinase anchor proteins (AKAPs), the mechanism of which has been applied in generation of bioactive conjugates of distinct protein and nonprotein molecules. This method allows quantitative and site-specific self-assembly of diverse biological moleculars applied for varirous medical purposes. Generally, our scientists apply DNL method to generate trivalent bispecific antibody which is composed of three Fab fragments. The advantage of this method is that this bispecific antibody form without a Fc region, which has a rather short half-life for pretargeting approaches. This format can be further extended to generate a hexavalent BsAb through linking DNL domains to the C-terminus of another antibody.

Figure: Diagram of a DNL-Fab3 (Drug Discov Today, 2015 )

Creative Biolabs provides a wide range of antibody engineering services that can accelerate your project from development stage to clinical trails. If you need more information, please do not hasitate to contact us.

Roland E. Kontermann and Ulrich Brinkmann. Bispecific antibodies. Drug Discov Today. 2015 Jul; 20(7):838-47.

Online Inquiry
Please input "biolabs"(case insensitive) as verification code.
45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-381-2994    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2018 Creative-Biolabs All Rights Reserved